Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shanghia, Shenzhen, Tianjin, Wenzhou, Xi'an
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
Early phase 1Not yet taking people in China
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Where
Tianjin
Age
18 years and over
People
24
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07539233
Phase 1Not yet taking people in China
BR101 in Patients With Relapsed/Refractory Multiple Myeloma
Where
Beijing
Age
18 years to 75 years
People
10
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07537049
Early phase 1Taking people
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Where
Beijing
Age
18 years to 90 years
People
30
Run by
Peking University First Hospital
See details and how to joinNCT06385652
Phase 1Taking people
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
Where
Chengdu
Age
18 years and over
People
138
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT06484777
Phase 1Taking people
Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Hangzhou, Jinan, Suzhou, Tianjin
Age
Up to 18 years
People
15
Run by
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
See details and how to joinNCT07529782
Phase 1/2Taking people
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Where
Shenzhen
Age
18 years to 75 years
People
96
Run by
Beijing Biotech
See details and how to joinNCT07523555
No phaseTaking people
Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study
Where
Taiyuan
Age
18 years and over
People
127
Run by
Shanxi Bethune Hospital
See details and how to joinNCT07514052
No phaseTaking people
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Where
Changchun
Age
18 years and over
People
50
Run by
FengYan Jin
See details and how to joinNCT06252792
Phase 2Taking people
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Where
Changchun
Age
18 years to 80 years
People
25
Run by
The First Hospital of Jilin University
See details and how to joinNCT07509086
No phaseTaking people
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Where
Taiyuan
Age
18 years to 75 years
People
48
Run by
Shanxi Bethune Hospital
See details and how to joinNCT07497165
Phase 3Taking people
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
358
Run by
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
See details and how to joinNCT07452198
Phase 2Taking people
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Where
Beijing
Age
14 years and over
People
25
Run by
Daihong Liu
See details and how to joinNCT07489534
Phase 1/2Taking people
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Where
Tianjin
Age
18 years to 50 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07169500
Phase 1/2Taking people
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Where
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
Age
18 years to 75 years
People
110
Run by
Gracell Biotechnologies (Shanghai) Co., Ltd.
See details and how to joinNCT06235229
Phase 1/2Taking people
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Where
Beijing
Age
8 years to 85 years
People
85
Run by
Essen Biotech
See details and how to joinNCT07410494
Phase 3Taking people
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Where
Ningbo
Age
18 years to 65 years
People
92
Run by
The Affiliated People's Hospital of Ningbo University
See details and how to joinNCT07413809
No phaseEnrolling by invitation
AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH Abnormalities
Where
Wuhan
People
10
Run by
Fuling Zhou
See details and how to joinNCT07410403
No phaseTaking people
National Longitudinal Cohort of Hematological Diseases
Where
Tianjin
People
2,300
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04645199
No phaseTaking people
Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Where
Changchun
Age
65 years and over
People
131
Run by
FengYan Jin
See details and how to joinNCT06099912
Early phase 1Not yet taking people in China
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）
Where
Beijing, Nanchang, Tianjin, Wuhan, Xuzhou, Zhengzhou
Age
18 years and over
People
38
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07399444
Phase 1Taking people
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Where
Beijing, Dalian, Foshan, Guangzhou, Hangzhou, Harbin, Jinan, Nanning, Taiyuan, Zhengzhou
Age
18 years to 75 years
People
70
Run by
Excyte Biopharma Ltd
See details and how to joinNCT06574568
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Beijing
Age
18 years and over
People
292
Run by
Sinocelltech Ltd.
See details and how to joinNCT07297329
No phaseNot yet taking people in China
A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
Where
Wuhan
Age
18 years to 78 years
People
28
Run by
Donghua Zhang
See details and how to joinNCT07376720
Phase 1Taking people
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Where
Guangzhou
Age
18 years to 75 years
People
18
Run by
O&D BioTech Group CO., Limited
See details and how to joinNCT07369895